| Autor: |
Edwards, Dawn1 (AUTHOR) dawn.m.webber@gsk.com, Best, N.1 (AUTHOR), Crawford, J.1 (AUTHOR), Zi, L.2 (AUTHOR), Shelton, C.3 (AUTHOR), Fowler, A.1 (AUTHOR) |
| Předmět: |
|
| Zdroj: |
Therapeutic Innovation & Regulatory Science. Jan2024, Vol. 58 Issue 1, p1-10. 10p. |
| Abstrakt: |
Bayesian Dynamic Borrowing (BDB) designs are being increasingly used in clinical drug development. These methods offer a mathematically rigorous and robust approach to increase efficiency and strengthen evidence by integrating existing trial data into a new clinical trial. The regulatory acceptability of BDB is evolving and varies between and within regulatory agencies. This paper describes how BDB can be used to design a new randomised clinical trial including external data to supplement the planned sample size and discusses key considerations related to data re-use and BDB in drug development programs. A case-study illustrating the planning and evaluation of a BDB approach to support registration of a new medicine with the Center for Drug Evaluation in China will be presented. Key steps and considerations for the use of BDB will be discussed and evaluated, including how to decide whether it is appropriate to borrow external data, which external data can be re-used, the weight to put on the external data and how to decide if the new study has successfully demonstrated treatment benefit. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Library, Information Science & Technology Abstracts |
| Externí odkaz: |
|
Full text from SpringerLink